SAN CARLOS, Calif., Feb. 9 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that it will hold the following events in February:
BIO CEO & Investor Conference 2006 Corporate Presentation February 14, 2006 11:30 a.m. ET Dr. Ted W. Love, Chairman & CEO http://www.corporate-ir.net/ ireye/confLobby.zhtml?ticker=NUVO&item_id=1165958 Focus Session CNS Disorders: Stroke -- Fighting the 3-Hour Window February 15, 20063:30 p.m. ETModerator: Elemer Piros, Senior Biotechnology Analyst of Rodman & Renshaw, LLC Expert: Dr. Howard Rowley of University of Wisconsin Panelists: Dr. Ted W. Love, Chairman & CEO of Nuvelo, Inc.; Dr. Wolfgang Soehngen, CEO of PAION; Paul E. Freiman, President & CEO of Neurobiological Technologies, Inc. and Dr. Alfred Bach, CEO of Axaron Bioscience AG http://ceo.bio.org/opencms/ceo/2006/index.jsp Fourth Quarter 2005 and Year End Financial Results and Accomplishments Conference Call & Webcast February 27, 2006 4:30 p.m. ET Dr. Ted W. Love, Chairman & CEO Lee Bendekgey, SVP & General Counsel Dr. Michael Levy, SVP, Research & Development Gary Titus, CFO & Chief Accounting Officer Dial in: 800-706-7748 domestic and 617-614-3473 international Conference Passcode: 99112652 Replay (available through March 13, 2006): 888-286-8010 domestic and 617-801-6888 international Conference Passcode: 60639452 Webcast: www.nuvelo.com or you can access it through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site. Live audio webcasts of the presentations will also be available online via the Investor Relations portion of Nuvelo’s website at www.nuvelo.com. About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo’s development pipeline includes alfimeprase, a direct-acting thrombolytic in Phase 3 clinical trials for the treatment of thrombotic-related disorders and rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that is currently in Phase 2 clinical development for acute coronary syndrome. Nuvelo is also progressing preclinical development candidates, NU206, for the potential treatment of chemotherapy/radiation therapy-induced mucositis, as well as a thrombin inhibiting aptamer. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 650-517-8000.
Nuvelo, Inc.
CONTACT: Nicole Estrin, Associate Director of Corporate Communications &IR of Nuvelo, Inc., +1-650-517-8472, or nestrin@nuvelo.com
Web site: http://www.nuvelo.com/
